Alnylam Q1 Earnings Beat but Execution Risks Remain

What happened

Alnylam reported Q1 2026 earnings of $1.99 per share, significantly beating the Zacks Consensus Estimate of $1.43 and swinging from a loss of $0.01 a year ago, driven by continued AMVUTTRA growth. However, the DeepValue report highlights that the stock remains sensitive to small revenue misses, as seen in Q4 2025 when AMVUTTRA sales of $827M missed forecasts of $852M–$861M, triggering a drawdown. The ongoing subpoena on government price reporting and distributor arrangements adds a compliance overhang that could compress net pricing if escalated. Meanwhile, BridgeBio's Attruby is gaining traction, with 6,629 unique prescriptions and 1,632 prescribers as of December 2025, threatening AMVUTTRA's new-start share. The company’s FY2026 combined net product revenue guidance of $4.9B–$5.3B remains the key barometer, and the market will scrutinize whether this quarter’s beat is a one-off or the start of a sustainable trend.

Implication

ALNY remains a WAIT at current levels. The Q1 beat provides some near-term support, but the thesis hinges on consistent AMVUTTRA cadence and stable net pricing. Investors should look for 1–2 more quarters of execution proof and a clearer resolution of the subpoena before committing capital. The attractive entry remains around $300, with a trim above $420.

Thesis delta

The Q1 earnings beat partially alleviates near-term execution anxiety, but it does not resolve the structural risks from the subpoena or competitive pressure from Attruby. The market's focus shifts from 'can they deliver' to 'can they sustain the pace without GTN erosion.' Until the next quarter provides cadence confirmation, the WAIT rating with a bias to underperformance on small misses remains intact.